Trump May Reclassify Marijuana - MMJ BioPharma To Escape The DEA's Seven Year Cannabis Trial Roadblock?
WASHINGTON, DC / ACCESS Newswire / August 11, 2025 / President Donald J. Trump is thinking about moving marijuana to a lower drug classification, according to the Wall Street Journal and other reports. If he does, it will finally crack open the door for companies like MMJ BioPharma Cultivation - and for patients who have been waiting far too long for real, FDA-approved cannabis medicines.
At a recent private fundraiser, Trump said he was looking at reclassifying marijuana from Schedule I - the same category as heroin - to Schedule III. This wouldn't make marijuana completely legal, but it would make a huge difference. It would loosen strict federal rules, open the door for more research, and let legitimate companies like MMJ BioPharma deduct normal business expenses. It could also speed up FDA clinical trials for new medicines.
For MMJ BioPharma, this change would be nothing short of a lifeline. 'Over the past seven years, we've poured millions of dollars into doing everything by the book', stated Duane Boise CEO.
We've done it all - except one thing: get the DEA's approval to grow the cannabis needed for our trials.
Seven Years, DEA No Action
Back in 2018, MMJ applied for a DEA license to grow pharmaceutical-grade cannabis for our FDA-approved research. That's the one piece we can't do without. And yet, after seven years, we're still waiting.
We've met every legal requirement. We've passed every inspection. We've followed every rule. But the DEA has refused to move forward.
This isn't just frustrating - it's directly against the Medical Marijuana and Cannabidiol Research Expansion Act, a law Congress passed in 2022 to speed up approvals for legitimate cannabis research. Instead of following the law, the DEA has buried our application in bureaucracy. Meanwhile, patients are left empty handed.
How Trump Could Break the Deadlock
When Trump reclassifies marijuana to Schedule III, it will tear down the DEA's most restrictive barriers to research. That would allow companies like ours to:
The Stakes Are Personal
While the DEA drags its feet, Trump is looking at issues that unite most Americans - the so-called '80-20 issues' that have wide support. Medical cannabis is one of them. Nearly everyone agrees that if a medicine can be proven safe and effective, patients should have access to it.
For MMJ BioPharma, the past seven years have been a master class in patience - and pain. We've built the labs, hired the scientists, perfected the medicine, and followed the rules to the letter. Yet we've been stuck in limbo because one agency won't do its job.
When Trump acts, it could finally end the waiting game. It would be a win for science, a win for patients, and a win for every company that plays by the rules.
If the DEA keeps dragging its heels, it will remain a textbook example of government failure - the kind that puts politics before patients.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Sumitomo Corporation Invests in Ursa Space to Accelerate Global Growth and Expand into Japan
ITHACA, N.Y., Aug. 20, 2025 /PRNewswire/ -- Ursa Space Systems, a leading provider of satellite-based analytic solutions, today announced a strategic investment from Sumitomo Corporation of Americas, the largest subsidiary of Sumitomo Corporation which is one of Japan's largest integrated trading and investment conglomerates. This investment marks a significant milestone in the company's expansion and strengthens its ability to serve customers across Asia, particularly in the Japanese market. As a global leader in geospatial AI solutions, Ursa Space delivers insights derived from the world's most comprehensive virtual constellation of commercial Earth observation data. The company's next-generation geospatial platform provides rapid, scalable, and automated remote sensing solutions to decision-makers across the commercial sector. "Partnering with Sumitomo as we expand into Japan positions us strongly for success," said Adam Maher, CEO of Ursa Space Systems. "We're thrilled by Sumitomo's investment and the trust they've placed in our vision. This partnership will enable us to bring the power of geospatial solutions to a wider audience and accelerate our mission to deliver insights at unmatched speed and scale." "We very much appreciate this opportunity to invest in and embark on a journey with Ursa Space Systems, one of the leading geospatial intelligence companies to offer AI-enabled user- friendly solution to the Japanese market," said Randy Yoshimura, SVP & General Manager of Sumitomo Corporation of Americas' Aerospace, Defense & Technology Group. Ursa Space's solutions are used to detect real-time changes in the physical world through multi-modal satellite imagery and data fusion, enabling customers to make confident, data-driven decisions. The company's subscription and custom monitoring services overcome traditional limitations of geography, weather, and political boundaries. With this new round of funding, Ursa Space will grow its capabilities, expand its reach into Asia, and further enhance its platform to meet the demands of a global customer base. The revolutionary orchestration capabilities of the company's platform represent a paradigm shift from image-first to indicator-first analysis. The simple user experience breaks down a complicated process that can take weeks into one that takes minutes. It provides analysts and operators with timely, easily accessible, and relevant commercial satellite solutions. Sumitomo joins existing investors in Ursa Space, which includes Dorilton Capital and RRE Ventures, among others. About Ursa Space Systems Ursa Space Systems builds the software and AI agents that guide the acquisition, analysis, and integration of satellite and geospatial data into customer workflows, delivering valuable insights for commodity markets. By leveraging satellite data and advanced analytics, Ursa Space provides fast, actionable information to a range of industries, including finance and energy. About Sumitomo Corporation Sumitomo Corporation (TYO: 8053) is an integrated trading and business investment company with a strong global network comprising 129 offices in 66 countries and regions. The Sumitomo Corporation Group consists of approximately 900 companies and 80,000 employees on a consolidated basis. The Group's business activities are spread across the following nine groups: Steel, Automotive, Transportation & Construction Systems, Diverse Urban Development, Media & Digital, Lifestyle Business, Mineral Resources, Chemicals Solutions and Energy Transformation Business. Sumitomo Corporation is committed to creating greater value for society under the corporate message of "Enriching lives and the world," based on Sumitomo's business philosophy passed down for over 400 years. View original content to download multimedia: SOURCE Ursa Space Systems
Yahoo
2 minutes ago
- Yahoo
US budget deficit forecast $1 trillion higher over next decade, watchdog says
By David Lawder WASHINGTON (Reuters) -U.S. federal budget deficits will be nearly $1 trillion higher over the next decade than projected in January by the Congressional Budget Office as a result of tax and spending legislation and tariffs, a budget watchdog said on Wednesday. The Committee for a Responsible Federal Budget's latest forecasts show a cumulative deficit of $22.7 trillion from fiscal 2026 to 2035, compared to the CBO's January forecast of $21.8 trillion, which was based on laws and policies that were in place before U.S. President Donald Trump took office in January. The CBO, Congress' non-partisan budget referee agency, said on Monday that it will not issue its customary mid-year budget update this year and will issue its next 10-year budget and economic outlook in early 2026, offering no explanation for the move. The CRFB, which advocates for deficit reduction, projected a $1.7 trillion deficit in fiscal 2025 or 5.6% of GDP, down slightly from $1.83 trillion in 2024 and the CBO's 2025 projection of $1.87 trillion in January. But it said deficits steadily rise over the decade, reaching $2.6 trillion or 5.9% of GDP by 2035. The new CRFB estimates include the budget effects of the One Big Beautiful Bill Act tax and spending bill, as well as Trump's tariffs that are currently in place. But like CBO, they do not include the dynamic economic effects on growth from these changes, a forecasting rule that has drawn criticism from the Trump administration. The group projects the tax cut and spending bill to increase deficits, including interest, by $4.6 trillion through 2035, adding another year to the CBO's $4.1 trillion cost estimate through 2034. But CRFB estimates that this will be offset by $3.4 trillion worth of extra import duty revenue over the next decade due to Trump's new tariffs that are currently in place. New rules restricting eligibility for health insurance subsidies will reduce deficits by another $100 billion through 2035, and Congress' rescission of prior funding to foreign aid, public broadcasting and other programs would save another $100 billion if sustained over a decade, CRFB said. Net interest payments on the national debt will total $14 trillion over the decade, CRFB projected, rising from nearly $1 trillion or 3.2% of GDP in 2025 to $1.8 trillion or 4.1% of GDP in 2035. TARIFF CHALLENGE The forecasts are based on legislative and tariff changes since January but keep CBO's economic forecasts unchanged. Under an alternative scenario forecast by CRFB, the budget picture looks far worse, boosting deficits nearly $7 trillion higher than the CBO baseline. This scenario would see a significant part of Trump's tariffs canceled if the Court of International Trade's ruling against many of Trump's new tariffs is upheld, cutting $2.4 trillion from revenues over a decade. The alternative scenario also assumes extension of a number of temporary tax cuts in the One Big Beautiful Bill Act, including tax breaks on overtime, tips, Social Security income and car loan interest, higher state and local tax deduction allowances and full expensing of factory investments, adding $1.7 trillion to deficits over 10 years. CRFB's alternative scenario also ditches the CBO's projection of a decline in 10-year U.S. Treasury yields over the decade to about 3.8%. If that interest rate stays at the current level of about 4.3%, interest costs would grow by about $1.6 trillion through 2035, CRFB said. The total 2035 debt-to-GDP ratio would grow from 118% in the CBO January baseline to 120% under the CRFB's projected baseline scenario and 134% under the CRFB's alternative scenario. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Raymond James Raises Infinity Natural Resources (INR) to $29 Amid Q2 Production Growth, Lower Operating Costs
Infinity Natural Resources Inc. (NYSE:INR) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 22, Raymond James analyst John Freeman raised the firm's price target on Infinity Natural Resources to $29 from $28, while maintaining a Strong Buy rating on the shares. While macro uncertainty remains, the oil prices are recovering, and so Raymond James sees minimal activity changes from management teams. Following this sentiment, Infinity Natural Resources held its Q2 2025 earnings call in August and reported a 25% production increase, with average daily production reaching 33.1 MBOE per day, up from 26.5 MBOE per day in Q1. This was a 28% year-over-year rise in net production due to the successful development of Marcellus Shale wells. A row of massive oil rigs in a desert landscape, against a setting sun. Infinity improved its efficiency, with operating costs per barrel of oil equivalent declining to $7.93 from $8.14 in Q2 2024. It also successfully accelerated a Pennsylvania natural gas project. The company's 2025 production outlook is between 32 and 35 MBOE per day, with capital expenditures for drilling and completion projected at $240 to $280 million, and midstream activities between $9 and $12 million. Infinity Natural Resources Inc. (NYSE:INR) acquires, explores, and develops properties to produce oil, natural gas, and natural gas liquids from underground reservoirs in the US. While we acknowledge the potential of INR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data
